SLVM Stock Analysis: Sylvamo | NYSE
Paper & Paper Products | NYSE, USA | Market Cap: 1.487m USD | 12M Return: -13% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.9M
EPS Trend: -76.4%
Qual. Beats: -1
Rev. Trend: -82.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 4.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sylvamo Corporation is a global producer of uncoated freesheet paper, operating in Europe, Latin America, and North America. The company manufactures cutsize, offset, and pulp products used for office printing, business forms, digital printing, book publishing, and commercial printing. Sylvamo sells its paper under multiple regional and product-specific brands, including REY, Berga, Multicopy, Chamex, Hammermill, Springhill, and Williamsburg, among others. The company operates both integrated mills (which produce pulp and paper) and non-integrated mills, and distributes its products through retail, merchant, and e-commerce channels to end users, converters, agents, resellers, and paper distributors. Headquartered in Memphis, Tennessee, Sylvamo was founded in 1898 and is listed on the NYSE under the ticker SLVM.
As a participant in the paper products sub-industry within the materials sector, Sylvamo operates in a mature, commodity-driven market that has faced long-term demand pressure from digital substitution in office and printing applications. The uncoated freesheet segment, which excludes coated glossier papers, primarily serves printing, writing, and copying end uses rather than packaging.
- Pulp and energy input costs pressure uncoated freesheet margins
- Latin America volume growth offsets European graphic paper demand decline
- Capital returns and debt reduction depend on free cash flow generation
| Net Income: 102.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -9.38 > 1.0 |
| NWC/Revenue: 10.32% < 20% (prev 10.71%; Δ -0.39% < -1%) |
| CFO/TA 0.08 > 3% & CFO 235.0m > Net Income 102.0m |
| Net Debt (851.0m) to EBITDA (384.0m): 2.22 < 3 |
| Current Ratio: 1.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.0m) vs 12m ago -2.44% < -2% |
| Gross Margin: 19.76% > 18% (prev 23.58%; Δ -3.83% > 0.5%) |
| Asset Turnover: 120.3% > 50% (prev 140.3%; Δ -20.06% > 0%) |
| Interest Coverage Ratio: 4.86 > 6 (EBIT TTM 204.0m / Interest Expense TTM 42.0m) |
| A: 0.12 (Total Current Assets 1.10b - Total Current Liabilities 758.0m) / Total Assets 2.83b |
| B: 0.88 (Retained Earnings 2.49b / Total Assets 2.83b) |
| C: 0.07 (EBIT TTM 204.0m / Avg Total Assets 2.73b) |
| D: 0.53 (Book Value of Equity 979.0m / Total Liabilities 1.85b) |
| Altman-Z'' = 4.71 = AA |
| DSRI: 1.01 (Receivables 398.0m/442.0m, Revenue 3.29b/3.69b) |
| GMI: 1.19 (GM 23.58% / 19.76%) |
| AQI: 0.37 (AQ_t 0.08 / AQ_t-1 0.22) |
| SGI: 0.89 (Revenue 3.29b / 3.69b) |
| TATA: -0.05 (NI 102.0m - CFO 235.0m) / TA 2.83b) |
| Beneish M = -3.30 (Cap -4..+1) = AA |
As of August 04, 2026, the stock is trading at USD 38.27 with a total of 190,298 shares traded. Over the past week, the price has changed by +1.49%, over one month by -1.01%, over three months by -8.13% and over the past year by -13.00%.
Current recommended Stop Loss: 35.70 (which is 6.7% or 1.7 ATR below the current price).
Sylvamo has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold SLVM.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 51.8 | 35.2% |
P/E Trailing = 14.9044
P/E Forward = 24.5098
P/S = 0.4525
P/B = 1.5184
Revenue TTM = 3.29b USD
EBIT TTM = 204.0m USD
EBITDA TTM = 384.0m USD
Long Term Debt = 766.0m USD (from longTermDebt, last quarter)
Short Term Debt = 174.0m USD (from shortTermDebt, last quarter)
Debt = 981.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 851.0m USD (calculated: Debt 981.0m - CCE 130.0m)
Enterprise Value = 2.34b USD (1.49b + Debt 981.0m - CCE 130.0m)
Interest Coverage Ratio = 4.86 (Ebit TTM 204.0m / Interest Expense TTM 42.0m)
EV/FCF = 233.8x (Enterprise Value 2.34b / FCF TTM 10.0m)
FCF Yield = 0.43% (FCF TTM 10.0m / Enterprise Value 2.34b)
FCF Margin = 0.30% (FCF TTM 10.0m / Revenue TTM 3.29b)
Net Margin = 3.11% (Net Income TTM 102.0m / Revenue TTM 3.29b)
Gross Margin = 19.76% ((Revenue TTM 3.29b - Cost of Revenue TTM 2.64b) / Revenue TTM)
Gross Margin QoQ = 11.13% (prev 26.29%)
Tobins Q-Ratio = 0.82 (Enterprise Value 2.34b / Total Assets 2.83b)
Interest Expense / Debt = 4.28% (Interest Expense 42.0m / Debt 981.0m)
Taxrate = 36.25% (58.0m / 160.0m)
NOPAT = 130.0m (EBIT 204.0m * (1 - 36.25%))
Current Ratio = 1.45 (Total Current Assets 1.10b / Total Current Liabilities 758.0m)
Debt / Equity = 1.00 (Debt 981.0m / totalStockholderEquity, last quarter 979.0m)
Debt / EBITDA = 2.22 (Net Debt 851.0m / EBITDA 384.0m)
Debt / FCF = 85.10 (Net Debt 851.0m / FCF TTM 10.0m)
Total Stockholder Equity = 970.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.73% (Net Income 102.0m / Total Assets 2.83b)
RoE = 10.51% (Net Income TTM 102.0m / Total Stockholder Equity 970.2m)
RoCE = 11.75% (EBIT 204.0m / Capital Employed (Equity 970.2m + L.T.Debt 766.0m))
RoIC = 6.13% (NOPAT 130.0m / Invested Capital 2.12b)
WACC = 6.40% (E(1.49b)/V(2.47b) * Re(8.82%) + D(981.0m)/V(2.47b) * Rd(4.28%) * (1-Tc(0.36)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -90.04 | Cagr: -2.15%
[DCF] Terminal Value 73.10% ; FCFF base≈108.4m ; Y1≈95.1m ; Y5≈76.8m
[DCF] Fair Price = 9.61 (EV 1.23b - Net Debt 851.0m = Equity 381.8m / Shares 39.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -76.43 | EPS CAGR: -26.20% | SUE: -1.75 | # QB: -1
Revenue Correlation: -82.83 | Revenue CAGR: -4.40% | SUE: 0.69 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=-86.87% | Revisions=-50% | Analysts=3
EPS next Quarter (2026-09-30): EPS=1.66 | Chg30d=+5.06% | Revisions=+29% | Analysts=3
EPS current Year (2026-12-31): EPS=2.03 | Chg30d=-13.11% | Revisions=-57% | GrowthEPS=-42.6% | GrowthRev=-0.2%
EPS next Year (2027-12-31): EPS=5.21 | Chg30d=-6.52% | Revisions=-29% | GrowthEPS=+156.4% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: -39% (up=4, down=11)